Jeffrey G. Supko
Division of Hematology/Oncology
Massachusetts General Hospital
Harvard Medical School
Boston 02114
USA
Name/email consistency: high
- Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Supko, J.G., Eder, J.P., Ryan, D.P., Seiden, M.V., Lynch, T.J., Amrein, P.C., Kufe, D.W., Clark, J.W. Clin. Cancer Res. (2003)
- Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. Supko, J.G., Garcia-Carbonero, R., Puchalski, T.A., Malspeis, L. Cancer Chemother. Pharmacol. (2001)